ABSTRACT
Leukopenia, thrombocytopenia, elevated D-dimer, and prolonged prothrombin time are considered poor prognostic factors in adults with acute Coronavirus Disease 2019. The prognostic significance of these abnormalities among pediatric patients remains underreported in the literature. This retrospective cohort study evaluates the prognostic implications of hematologic and hemostatic derangements in patients younger than 22-years-of-age who were admitted to a tertiary-care referral institution for management of acute Coronavirus Disease 2019 infection. Leukopenia and thrombocytopenia were identified as independent prognostic factors of disease severity. Although the majority of children, with available results, had elevated D-dimer or prolonged prothrombin time upon initial presentation, these markers were not found to be associated with the development of severe clinical complications.
Subject(s)
COVID-19/blood , Hemostasis , Adolescent , Adult , COVID-19/complications , COVID-19/diagnosis , Child , Child, Preschool , Female , Fibrin Fibrinogen Degradation Products/analysis , Humans , Infant , Leukopenia/blood , Leukopenia/complications , Leukopenia/diagnosis , Male , Prognosis , Retrospective Studies , SARS-CoV-2/isolation & purification , Severity of Illness Index , Thrombocytopenia/blood , Thrombocytopenia/complications , Thrombocytopenia/diagnosis , Young AdultABSTRACT
This case aims to remind all providers to scrutinise for atypical presentations of multisystem inflammatory syndrome in children (MIS-C) which may mimic a more routine diagnosis. In the absence of mucocutaneous symptoms, the diagnosis of MIS-C can be missed. Given the potential for rapid deterioration of patients with MIS-C, early treatment and inpatient interventions are necessary.
Subject(s)
Abdominal Pain/immunology , COVID-19/diagnosis , Fever/immunology , SARS-CoV-2/isolation & purification , Systemic Inflammatory Response Syndrome/diagnosis , Tachycardia/immunology , Abdominal Pain/blood , Abdominal Pain/therapy , Abdominal Pain/virology , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Alanine/analogs & derivatives , Alanine/therapeutic use , C-Reactive Protein/analysis , COVID-19/blood , COVID-19/immunology , COVID-19/therapy , COVID-19 Nucleic Acid Testing , COVID-19 Serological Testing , Child , Diagnosis, Differential , Fever/blood , Fever/therapy , Fever/virology , Humans , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Intubation, Intratracheal , Male , Mucocutaneous Lymph Node Syndrome/diagnosis , Myocarditis/diagnosis , Nasopharynx/virology , Natriuretic Peptide, Brain/blood , SARS-CoV-2/immunology , Systemic Inflammatory Response Syndrome/blood , Systemic Inflammatory Response Syndrome/immunology , Systemic Inflammatory Response Syndrome/therapy , Tachycardia/blood , Tachycardia/therapy , Tachycardia/virology , Treatment Outcome , COVID-19 Drug TreatmentABSTRACT
Engineered camelid antibody multimers can potently block SARS-CoV-2 viral entry.